CONTACT US

NEW HIV VACCINE AND
MICROBICIDE ADVOCACY SOCIETY
Address: 44B,Ijaye Road,Ogba,
Lagos,Nigeria
email: info@nhvmas-ng.org
Tel:234-018195255

Send us a feedback

Name
E-mail
Note Type
Subject
Message

Photo Speak

NHVMAS NEWS

	Cure for HIV: A prize to keep our eyes on

	Rethinking the risk factors for sexual risk among young persons: the evidence from analysis of South Africa and the USA

	The need to discuss a rectal microbicide agenda for Nigeria

	Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study

	Use of injectible hormonal contraceptives and risk of HIV-1 transmission

	End of project report: Building capacity of laypersons to communicate NPT trial results

	A simpler tool for estimation of HIV incidence from cross-sectional, age-specific prevalence data

	Age related HIV incidence among sex workers

	HIV incidence data for FSW in Nassarawa - Report from Biotech Initative, Nigeria

	Treating HIV-infected People with Antiretrovirals Protects HIV-negative Partners from Infection

	Adaptive Clinical Trials Design - Part II

	Adaptive Trial Design 1: An Overview

	Perceptive survey highlights growing interest in adaptive trial designs

	The New HIV Vaccine and Microbicide Advocacy Society announces its training schedule for 2011

	Workshop on Interpreting and communicating biomedical HIV prevention research trial results

	One antiretroviral pill a day may keep HIV infection away: call for action NHVMAS outlines potential next steps for the Nigerian Community

	Understanding Combination Prevention: the way forward for effective HIV prevention

	Cure for HIV infection must now be major scientific priority, Vienna AIDS conference hears

	NHVMAS statement on CAPRISA 004

	NHVMAS statement on MDP 301 result:

	NHVMAS celebrates its 7th Anniversary with funfare!!!!

	Lack of effectiveness of Cellulose Sulphate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463-72.

	A Brief History of New HIV Prevention Research

	NHVMAS at ICASA 2008

	New HIV Prevention Technology research: the Nigeria story

	Update on the aborted HIV Vaccine trial -

	Future access to Microbicides

	Advocates in Nigeria disappointed with the Carraguard study result and advocates for continued research efforts on Microbicide

	Roundtable proffers ways of respecting the rights of participants in

	No associations between the use of Lemon Juice douching and other STI

	Different types of Microbicides

	Glossary of terms used in microbicides research

	M2008:Do you understand the language of Microbicides research

	New lessons on HIV infection route

	The diaphragm: A Female-initiated barrier methods

	HSV-2 suppression: efforts at preventing HIV infection

	Post exposure Prophylaxis (PeP)

	New HIV Prevention technology pipelines - ARV treatment of index partners

	New HIV prevention technology pipelines - the story of PreP

	New HIV Prevention Technologies - HIV Vaccines

	Prevention of Mother to Child Transmission (PMTCT)

	Interpreting the results of HIV prevention trials (2)

	Interpreting the results of HIV prevention trials (3) - So far so...

	Could vaginal microbicides protect men more so than women?

	HSV-2 treatment does not reduce the risk of HIV infection.

	Identified risk factor for HIV infection in women

	When microbicide clinical trials end: lessons learnt and role of advocates

	SAVVY trial result dissemination efforts in Lagos, Nigeria

	NHVMAS members make it to the IRMA Board

	The thrill about the HPTN 035 study

	What would the face of HIV control be in the next 25 years?

	RELATED NEWS
	Dramatic lessons from trial closures in Cambodia and Cameroon http://www.global-campaign.org/GCArchives.htm Microbicide development: positive women's concern http://www.sfaf.org/beta/ 2009_win/women